More than 6,000,000 Americans are living with Alzheimer's disease – it slowly steals your memories and takes away your mind ...

There is no cure yet, but now, a newly FDA-approved drug is helping to slow its progression before it’s too late.

FDA approves much-debated Alzheimer’s drug panned by experts June 8, 2021 Alzheimer’s drug from Eisai and Biogen slows cognitive decline, side-effects in focus ...

The largest biopharmas are succeeding in overcoming the so-called patent cliff of sharply reduced future sales as existing blockbuster drugs lose patent protection—at least over the next five years, a ...

The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm’s stem cell-based treatment has not ...

The Food and Drug Administration recently laid out a proposal to begin regulating laboratory medical tests, a multibillion-dollar industry the agency says poses a growing risk to patients because of ...

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.

We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...

USC researchers played a key role in a new treatment for Alzheimer’s disease, the first with full approval to target a suspected root cause of the condition, offering hope to those with the disease ...

For anyone who has or knows someone who has Alzheimer’s disease, a progressive and irreversible form of dementia that’s ultimately deadly, it can sometimes be difficult to find hope.

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S.